A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)

This is an interventional trial. The goal of this clinical trial is dose finding. There are two phases: phase Ib to determine the MTD and recommended phase II dose of niraparib in combination with abemaciclib in patients with advanced ovarian cancer. Target population will be patients (woman, age \> 18 years) with epithelial ovarian, fallopian tube or peritoneal cancer treated with at least 2 lines of therapy.

Trial Details

NCT ID
NCT06594679
Phase
PHASE1 / PHASE2
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Niraparib Tosylate Monohydrate
Locations (sample)
  • Milan, Milano, Italy|42.78235,12.59836

Key Eligibility Criteria

  • Has read and understands the informed consent form and has given written informed consent prior to any study procedures.
  • Age \> 18 years
  • Life expectancy of at least 3 months
  • Histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →